These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6459663)

  • 1. On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin.
    Barlow GH; Francis CW; Marder VJ
    Thromb Res; 1981 Sep; 23(6):541-7. PubMed ID: 6459663
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion of Glu-plasminogen to plasmin by urokinase in the presence of tranexamic acid.
    Takada A; Takada Y
    Thromb Res; 1981 May; 22(4):437-43. PubMed ID: 6457415
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoclonal antibodies inhibitory to human plasmin. Definitive demonstration of a role for plasmin in activating the proenzyme of urokinase-type plasminogen activator.
    Sim PS; Fayle DR; Doe WF; Stephens RW
    Eur J Biochem; 1986 Aug; 158(3):537-42. PubMed ID: 2942403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro study of a human plasmin (CY 218) and its association with urokinase (author's transl)].
    Brochier M; Griguer P
    Rev Med Brux; 1981 Mar; 2(3):167-74. PubMed ID: 6453415
    [No Abstract]   [Full Text] [Related]  

  • 5. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
    Summaria L; Boreisha IG; Arzadon L; Robbins KC
    Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
    [No Abstract]   [Full Text] [Related]  

  • 7. Kinetic studies of the urokinase-catalysed conversion of NH2-terminal glutamic acid plasminogen to plasmin.
    Christensen U
    Biochim Biophys Acta; 1977 Apr; 481(2):638-47. PubMed ID: 139931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of three different molecular forms of the alpha 2 plasmin inhibitor.
    Clemmensen I; Thorsen S; Müllertz S; Petersen LC
    Eur J Biochem; 1981 Nov; 120(1):105-12. PubMed ID: 6458494
    [No Abstract]   [Full Text] [Related]  

  • 9. Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator.
    Lijnen HR; Collen D
    Thromb Res; 1986 Sep; 43(6):687-90. PubMed ID: 2945283
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation.
    Geratz JD; Shaver SR; Tidwell RR
    Thromb Res; 1981 Oct 1-15; 24(1-2):73-83. PubMed ID: 6460342
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of vitreous clot lysis by urokinase: mode of action.
    Forrester JV; Edgar W; Millar W; Prentice CR; Williamson J
    Exp Eye Res; 1982 Jun; 34(6):895-907. PubMed ID: 6211365
    [No Abstract]   [Full Text] [Related]  

  • 13. Positive regulation of activation of plasminogen by urokinase: differences in Km for (glutamic acid)-plasminogen and lysine-plasminogen and effect of certain alpha, omega-amino acids.
    Peltz SW; Hardt TA; Mangel WF
    Biochemistry; 1982 May; 21(11):2798-804. PubMed ID: 6212078
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanism of action of fibrinolytic enzymes in vivo.
    Ambrus JL; Weber FJ; Ambrus CM
    J Med; 1979; 10(1-2):99-119. PubMed ID: 158624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic studies of the urokinase catalysed conversion of NH2-terminal lysine plasminogen to plasmin.
    Christensen U; Müllertz S
    Biochim Biophys Acta; 1977 Jan; 480(1):275-81. PubMed ID: 137749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of plasmin on human plasma low density lipoprotein.
    Steele JC
    Thromb Res; 1979; 15(3-4):573-9. PubMed ID: 227127
    [No Abstract]   [Full Text] [Related]  

  • 17. Covalent molecular weight approximately 92 000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxyl-terminal domains.
    Robbins KC; Tanaka Y
    Biochemistry; 1986 Jun; 25(12):3603-11. PubMed ID: 2941075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of plasmin catalyzed conversion of single-chain to two-chain urokinase-type plasminogen activator by sulfated polysaccharides.
    Rydzewski A; Takada Y; Takada A
    Thromb Haemost; 1989 Sep; 62(2):752-5. PubMed ID: 2479114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
    Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H
    Adv Exp Med Biol; 1991; 297():111-28. PubMed ID: 1837419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cider on the fibrinolytic enzyme system.
    Anderson JA; Gow LA; Ogston D
    Acta Haematol; 1983; 69(5):344-8. PubMed ID: 6220562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.